Breaking News, Collaborations & Alliances

Dragonfly, Merck Enter Strategic Collaboration

To discover, develop and commercialize innovative immunotherapies for patients with solid tumor cancers

Dragonfly Therapeutics announced a strategic collaboration with Merck, through a subsidiary, to discover, develop and commercialize innovative immunotherapies for patients with solid tumor cancers.    The collaboration grants Merck the option to license exclusive worldwide intellectual property rights to products developed using Dragonfly’s TriNKET™ technology platform for a number of solid-tumor programs, with the potential to earn Dragonfly up to $695 million in up front and mile...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters